Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders

Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders

  • Post published:April 19, 2023
  • Post category:Press Release
Read more about the article Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia

Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia

  • Post published:March 27, 2023
  • Post category:Press Release
Read more about the article Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia

Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia

  • Post published:March 15, 2023
  • Post category:Press Release
Read more about the article Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s

Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s

  • Post published:February 13, 2023
  • Post category:Press Release
Read more about the article Silo Pharma Announces Expansion of Intellectual Property Portfolio

Silo Pharma Announces Expansion of Intellectual Property Portfolio

  • Post published:February 2, 2023
  • Post category:Press Release
Read more about the article Silo Pharma Announces Stock Repurchase Program

Silo Pharma Announces Stock Repurchase Program

  • Post published:January 31, 2023
  • Post category:Press Release
Read more about the article Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

  • Post published:January 13, 2023
  • Post category:Press Release
Read more about the article Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine

  • Post published:December 1, 2022
  • Post category:Press Release
Read more about the article Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

  • Post published:November 29, 2022
  • Post category:Press Release
Read more about the article Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

  • Post published:October 26, 2022
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More